Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by TransCode Therapeutics, Inc. < Previous 1 2 Next > TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance November 05, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data October 23, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology October 10, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate September 17, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer September 10, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate September 05, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation August 15, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics, Inc. Announces Closing of Public Offering July 24, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics, Inc. Announces Pricing of Public Offering July 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock July 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements June 10, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 May 29, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Open Letter to Shareholders May 13, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors April 15, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Reports 2023 Results; Provides Business Update April 03, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer March 28, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment March 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress March 06, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic February 20, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market January 31, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer January 29, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Closing of $7.25 Million Public Offering January 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering January 18, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO January 12, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces 1-for-40 Reverse Stock Split January 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives January 04, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 December 12, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium December 05, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules December 04, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules November 30, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire Tickers RNAZ < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
